首页> 外文期刊>International journal of clinical oncology >Pulmonary metastasectomy in patients with renal cell carcinoma: A single-institution experience
【24h】

Pulmonary metastasectomy in patients with renal cell carcinoma: A single-institution experience

机译:肾细胞癌患者的肺转移切除术:单机构经验

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Pulmonary metastasectomy in patients with renal cell carcinoma (RCC) remains controversial. The purpose of our analysis was to explore the outcome of patients with RCC who underwent pulmonary metastasectomy at our institution. Methods: We reviewed data on 25 patients who underwent resection of lung metastasis from 1998 to 2008 at our institution. Results: All patients were treated by radical nephrectomy for primary RCC. Progression-free survival (PFS) ranged from 0.3 to 198.8 months (median 7.4 months), and overall survival (OS) ranged from 2.4 to 198.8 months (median 33.9 months). The 5-year PFS rate was 24.9%, and the OS rate was 35.5%. Although differences in the resectability of the metastasectomy and OS were not significant in univariate or multivariate analyses, the relationship between PFS and the radicality of pulmonary metastasectomy was significant in both the univariate and multivariate analyses (P = 0.004, 0.012, respectively). Conclusions: The results of pulmonary metastasectomy for patients with RCC at our institution indicate that pulmonary metastasectomy should be performed only when the pulmonary metastasis can be completely resected. Additional studies are therefore necessary to evaluate the prognostic factors and to determine the selection criteria for pulmonary metastasectomy in the new era of molecular-targeted agents.
机译:背景:肾细胞癌(RCC)患者的肺转移切除术仍存在争议。我们分析的目的是探讨在我们机构接受过肺转移的RCC患者的结局。方法:我们回顾了1998年至2008年在我院进行的25例行肺转移切除术的患者的数据。结果:所有患者均接受了根治性肾切除术治疗原发性RCC。无进展生存期(PFS)为0.3到198.8个月(中位数为7.4个月),总生存期(OS)为2.4到198.8个月(中位数33.9个月)。 5年PFS率为24.9%,OS率为35.5%。尽管在单因素或多因素分析中,转移灶切除术和OS的可切除性差异不显着,但在单因素和多因素分析中,PFS和肺转移灶根治性之间的关系均很显着(分别为P = 0.004、0.012)。结论:我们机构对RCC患者进行肺转移切除术的结果表明,只有在可以完全切除肺转移的情况下才应进行肺转移切除术。因此,在分子靶向药物新时代,需要进行更多的研究来评估预后因素并确定肺转移的选择标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号